Hector Ubaldo, MD
Internal Medicine · Katy, TXNPI 1790795383
Payments from drug & device makers
Across 110 payments — averaging $58.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Photonicare Inc$5K
- Abbott$327
- Novo Nordisk$212
- GSK$119
- Antares Pharma, Inc.$98
- AbbVie$87
- plus $653 from 25 others
What the payments were for
- Food & beverage$1,41022%
- Education$851%
- Other$4,93477%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Photonicare Inc | 1 | $4,934 |
| Abbott | 40 | $327 |
| Novo Nordisk | 14 | $212 |
| GSK | 6 | $119 |
| Antares Pharma, Inc. | 7 | $98 |
| AbbVie(2 entities) | 4 | $87 |
| Astellas Pharma US Inc | 1 | $85 |
| Pfizer | 4 | $60 |
| Boehringer Ingelheim | 4 | $57 |
| Amarin Pharma, Inc. | 3 | $46 |
| Halozyme Inc | 3 | $45 |
| Sanofi-aventis U.S. LLC | 2 | $32 |
| Sunovion Pharmaceuticals Inc. | 2 | $29 |
| Corium, LLC | 1 | $25 |
| Supernus Pharmaceuticals, Inc. | 1 | $22 |
| Pulmonx Corporation | 1 | $21 |
| Verity Pharmaceuticals Inc. | 1 | $21 |
| Neuronetics, Inc. | 1 | $21 |
| Kowa Pharmaceuticals America, Inc. | 1 | $20 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
| Renalytix AI, Inc. | 1 | $17 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
| Hikma Pharmaceuticals USA | 1 | $15 |
| Amgen | 1 | $15 |
| Lilly USA, LLC | 1 | $14 |
| Acerus Pharmaceuticals Corporation | 1 | $13 |
| Johnson & Johnson | 1 | $13 |
| AstraZeneca | 1 | $13 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $13 |
| Cumberland Pharmaceuticals, Inc. | 1 | $11 |
| Fidia Pharma USA Inc. | 2 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,429 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 133 | $154,126 |
| EliquisApixaban | 65 | $79,425 |
| JanuviaSitagliptin Phosphate | 42 | $56,112 |
| MyrbetriqMirabegron | 67 | $51,133 |
| MounjaroTirzepatide | 37 | $49,140 |
| JardianceEmpagliflozin | 24 | $21,352 |
| Tresiba Flextouch U-200Insulin Degludec | 16 | $17,945 |
| JanumetSitagliptin Phos/Metformin Hcl | 12 | $17,567 |
| Tresiba Flextouch U-100Insulin Degludec | 15 | $17,353 |
| LinzessLinaclotide | 11 | $16,936 |
| XareltoRivaroxaban | 16 | $16,766 |
| GemtesaVibegron | 22 | $15,897 |
| VascepaIcosapent Ethyl | 23 | $13,219 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 38 | $12,683 |
| Testosterone | 20 | $6,840 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $212 | $154,126133 claims |
| PfizerEliquis | $60 | $79,42565 claims |
| Astellas Pharma US IncMyrbetriq | $85 | $51,13367 claims |
| Lilly USA, LLCMounjaro | $14 | $49,14037 claims |
| Boehringer IngelheimJardiance | $57 | $21,35224 claims |
| AbbVieLinzess, Synthroid | $87 | $18,79433 claims |
| Johnson & JohnsonXarelto | $13 | $16,76616 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $19 | $15,89722 claims |
| AstraZenecaSymbicort | $13 | $5,63912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Katy
- Jan BurgerHouston$47.3M
- Nitin JainHouston$33.2M
- Muhammad IrfanTomball$30.6M
- Aung NaingHouston$30.6M
- Robert BassSan Antonio$25.6M
- Preetesh JainHouston$19.5M
- Paolo StratiHouston$19.2M
- Hernan SalazarSan Antonio$18.5M
- Nicholas ShortHouston$17.6M
- Salma SaigerMesquite$16.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.